Jide Xu

Effect of hydroxamate siderophores on Fe release and Pb(II) adsorption by goethite

Abstract Hydroxamate siderophores are biologically-synthesized, Fe(III)-specific ligands which are common in soil environments. In this paper, we report an investigation of their adsorption by the iron oxyhydroxide, goethite; their influence on goethite dissolution kinetics; and their ability to affect Pb(II) adsorption by the goethite surface. The siderophores used were desferrioxamine B (DFO-B), a fungal siderophore, and desferrioxamine D1, an acetyl derivative of DFO-B (DFO-D1). Siderophore adsorption isotherms yielded maximum surface concentrations of 1.5 (DFO-B) or 3.5 (DFO-D1) μmol/g at pH 6.6, whereas adsorption envelopes showed either cation-like (DFO-B) or ligand-like (DFO-D1) behavior. Above pH 8, the adsorbed concentrations of both siderophores were similar. The dissolution rate of goethite in the presence of 240 μM DFO-B or DFO-D1 was 0.02 or 0.17 μmol/g hr, respectively. Comparison of these results with related literature data on the reactions between goethite and acetohydroxamic acid, a monohydroxamate ligand, suggested that the three hydroxamate groups in DFO-D1 coordinate to Fe(III) surface sites relatively independently. The results also demonstrated a significant depleting effect of 240 μM DFO-B or DFO-D1 on Pb(II) adsorption by goethite at pH > 6.5, but there was no effect of adsorbed Pb(II) on the goethite dissolution rate.

Selective removal of lanthanides from natural waters, acidic streams and dialysate

The increased demand for the lanthanides in commercial products result in increased production of lanthanide containing ores, which increases public exposure to the lanthanides, both from various commercial products and from production wastes/effluents. This work investigates lanthanide (La, Ce, Pr, Nd, Eu, Gd and Lu) binding properties of self-assembled monolayers on mesoporous silica supports (SAMMS), that were functionalized with diphosphonic acid (DiPhos), acetamide phosphonic acid (AcPhos), propionamide phosphonic acid (Prop-Phos), and 1-hydroxy-2-pyridinone (1,2-HOPO), from natural waters (river, ground and sea waters), acid solutions (to mimic certain industrial process streams), and dialysate. The affinity, capacity, and kinetics of the lanthanide sorption, as well as regenerability of SAMMS materials were investigated. Going from the acid side over to the alkaline side, the AcPhos- and DiPhos-SAMMS maintain their outstanding affinity for lanthanides, which enable the use of the materials in the systems where the pH may fluctuate. In acid solutions, Prop-Phos- and 1,2-HOPO-SAMMS have differing affinity along the lanthanide series, suggesting their use in chromatographic lanthanide separation. Over 95% of 100 microg/L of Gd in dialysate was removed by the Prop-Phos-SAMMS after 1 min and 99% over 10 min. SAMMS can be regenerated with an acid wash (0.5M HCl) without losing the binding properties. Thus, they have a great potential to be used as in large-scale treatment of lanthanides, lanthanide separation prior to analytical instruments, and in sorbent dialyzers for treatment of acute lanthanide poisoning.

meso Myths: What Drives Assembly of Helical versus meso‐[M2L3] Clusters?

Both a triple helix as well as a meso complex are formed by the Ga(III) and Al(III) complexes with a bis-bidentate bis-hydroxypyridinone ligand H(2)L. The two forms are in equilibrium in solution, though formation of the helical structure in the presence of water, which as guest molecule finds sufficient space in the cavity of the helix, is favored (the structure of the helical H(2)O subset[Al(2)L(3)] complex is shown).

3‐Hydroxypyridin‐2‐one Complexes of Near‐Infrared (NIR) Emitting Lanthanides: Sensitization of Holmium(III) and Praseodymium(III) in Aqueous Solution

There is a growing interest in Near Infra-Red (NIR) emission originating from organic complexes of LnIII cations.[1,2] As a major impetus, biological tissues are considerably more transparent at these low energy wavelengths when compared to visible radiation, which facilitates deeper penetration of incident and emitted light.[3] Furthermore, the long luminescence lifetimes of LnIII complexes (eg. YbIII, τrad ~ 1 ms) when compared to typical organic molecules can be utilized to vastly improve signal to noise ratios by employing time-gating techniques. While the improved quantum yield of YbIII complexes when compared to other NIR emitters favours their use for bioimaging applications, there has also been significant interest[4,5,6] in the sensitized emission from other 4f metals such as Ln = Nd, Ho, Pr and Er which have well recognised applications as solid state laser materials[7] (eg. Nd ~ 1.06 μm, Ho ~ 2.09 μm), and in telecommunications (eg. Er ~ 1.54 μm) where they can be used for amplification of optical signals.[8]

New agents for in vivo chelation of uranium(VI): efficacy and toxicity in mice of multidentate catecholate and hydroxypyridinonate ligands.

Soluble uranyl ion [UO2(2+), U(VI)] is a kidney poison. Uranyl ion accumulates in bone, and the high specific activity uranium isotopes induce bone cancer. Although sought since the 1940s, no multidentate ligand was identified, until now, that efficiently and stably binds U(VI) at physiological pH, promotes its excretion, and reduces deposits in kidneys and bone. Ten multidentate ligands patterned after natural siderophores and composed of sulfocatechol [CAM(S)], carboxy-catechol [CAM(C)], or hydroxypyridinone [Me-3,2-HOPO] metal-binding units have been tested for in vivo chelation of U(VI). Ligands were injected intraperitoneally (i.p.) into mice 3 min after intravenous (i.v.) injection of 233U or (232+235)U as UO2Cl2 [ligand-to-metal molar ratio 75 to 92]. Regardless of backbone structure, denticity, or binding unit, all 10 ligands significantly reduced kidney U(VI) compared with controls or with mice given CaNa3-DTPA, and four CAM(S) or CAM(C) ligands also significantly reduced skeleton U(VI). Several ligands removed U(VI) from kidneys, when injected at 1 or 24 h. Injected at molar ratios > or = 300, 5-LIO(Me-3,2-HOPO) and TREN-(Me-3,2-HOPO) reduced kidney U(VI) to about 10% of control. Given orally to fasted mice at molar ratios > or = 300, those ligands significantly reduced kidney U(VI). In mice injected i.v. with 0.42 micromol kg(-1) of 235U and given 100 micromol kg(-1) of one of those Me-3,2-HOPO ligands i.p. daily for 10 d starting at 1 h after the U(VI)) loss of kidney U(VI) was greatly accelerated, and the kidneys of treated mice showed no microscopic evidence of renal injury. Crystals of uranyl chelates with linear tetradentate ligands containing bidentate Me-3,2-HOPO groups demonstrate a 1:1 structure. Considering low toxicity, effectiveness, and reasonable cost, the structurally simple linear tetradentate ligands based on the 5-LI backbone (diaminopentane) offer the most promising approach to a clinically acceptable therapeutic agent for U(VI). Work is in progress to identify the most suitable CAM or HOPO binding unit(s).

Predicting Efficient Antenna Ligands for Tb(III) Emission

A series of highly luminescent Tb(III) complexes of para-substituted 2-hydroxyisophthalamide ligands (5LI-IAM-X) has been prepared (X = H, CH(3), (CO)NHCH(3), SO(3)(-), NO(2), OCH(3), F, Cl, Br) to probe the effect of substituting the isophthalamide ring on ligand and Tb(III) emission in order to establish a method for predicting the effects of chromophore modification on Tb(III) luminescence. The energies of the ligand singlet and triplet excited states are found to increase linearly with the pi-withdrawing ability of the substituent. The experimental results are supported by time-dependent density functional theory calculations performed on model systems, which predict ligand singlet and triplet energies within approximately 5% of the experimental values. The quantum yield (Phi) values of the Tb(III) complexes increase with the triplet energy of the ligand, which is in part due to decreased non-radiative deactivation caused by thermal repopulation of the triplet. Together, the experimental and theoretical results serve as a predictive tool that can guide the synthesis of ligands used to sensitize lanthanide luminescence.

SELF-ASSEMBLY OF A THREE-DIMENSIONAL GA6(L2)6 METAL-LIGAND CYLINDER

A near trigonal antiprism with metal–metal distances in the nanometer regime is formed by the six metal ions in the crystalline, homochiral [Ga6(L2)6] (see structure). This metal–ligand “cylinder” is based on a threefold symmetric, β-diketone ligand, and represents a new geometry for metal–ligand clusters.

A single sensitizer for the excitation of visible and NIR lanthanide emitters in water with high quantum yields.

The versatile octadentate TIAM ligand forms lanthanide (Sm, Eu, Tb, Dy, Ho) complexes with high quantum yields in water. This ligand is an efficient sensitizer, and also shields the metal center from solvent quenching, as shown by an X-ray diffraction study of the Ho complex.

Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates.

Abstract. For decades, desferrioxamine B (Desferal) has been the therapeutic iron chelator of choice for iron-overload treatment, despite numerous problems associated with its use. Consequently, there is a continuous search for new iron chelating agents with improved properties, particularly oral activity. We have studied new potential therapeutic iron sequestering agents: multidentate ligands containing the hydroxypyridonate (HOPO) moiety. The ligands TRENCAM-3,2-HOPO, TRPN-3,2-HOPO, TREN-Me-3,2-HOPO, TREN-1,2,3-HOPO, 5LIO-3,2-HOPO, and BU-O-3,4-HOPO have been examined for their ability to remove iron from human diferric transferrin. The iron removal ability of the HOPO ligands is compared with that of the hydroxamate desferrioxamine B, the catecholates TRENCAM and enterobactin, as well as the bidentate hydroxypyridonate deferiprone, a proposed therapeutic substitute for Desferal. All the tested HOPO ligands efficiently remove iron from diferric transferrin at millimolar concentrations, with a hyperbolic dependence on ligand concentration. At high ligand concentrations, the fastest rates are found with the tetra- and bidentate hydroxypyridonates 5LIO-3,2-HOPO and deferiprone, and the slowest rates with the catecholate ligands. At low concentrations, closer to therapeutic dosage, hexadentate ligands which possess high pM values have the fastest rates of iron removal. TRENCAM-3,2-HOPO and TREN-Me-3,2-HOPO are the most efficient at lower doses and are regarded as having high potential as therapeutic agents. The kinetics of removal of Ga(III) from transferrin [in place of the redox active Fe(III)] were performed with TRENCAM and TREN-Me-3,2-HOPO to determine that there is no catalytic reduction step involved in iron removal.

Chelating agents for uranium(VI) : 2. efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice

Uranium(VI) (UO22+, uranyl) is nephrotoxic. Depending on isotopic composition and dosage, U(VI) is also chemically toxic and carcinogenic in bone. Several ligands containing two, three, or four bidentate catecholate or hydroxypyridinonate metal binding groups, developed for in vivo chelation of other actinides, were found, on evaluation in mice, to be effective for in vivo chelation of U(VI). The most promising ligands contained two bidentate groups per chelator molecule (tetradentate) attached to linear 4- or 5-carbon backbones (4-LI, butylene; 5-LI, pentylene; 5-LIO, diethyl ether). New ligands were then prepared to optimize ligand affinity for U(VI) in vivo and low acute toxicity. Five bidentate binding groups—sulfocatechol [CAM(S)], carboxycatechol [CAM(C)], methylterephthalamide (MeTAM), 1,2-hydroxypyridinone (1,2-HOPO), or 3,2-hydroxypyridinone (Me-3,2-HOPO)—were each attached to two linear backbones (4-LI and 5-LI or 5-LIO). Those ten tetradentate ligands and octadentate 3,4,3-LI(1,2-HOPO), an effective actinide chelator, were evaluated in mice for in vivo chelation of 233U(VI) (injection at 3 min, 1 h, or 24 h or oral administration at 3 min after intravenous injection of 233UO2Cl2) and for acute toxicity (100 &mgr;mol kg−1 injected daily for 10 d). The combined efficacy and toxicity screening identified 5-LIO(Me-3,2-HOPO) and 5-LICAM(S) as the most effective low-toxicity agents. They chelate circulating U(VI) efficiently at ligand:uranium molar ratios ≥ 20, remove useful amounts of newly deposited U(VI) from kidney and bone at molar ratios ≥ 100, and reduce kidney U(VI) levels significantly when given orally at molar ratios ≥ 100. 5-LIO(Me-3,2-HOPO) has greater affinity for kidney U(VI) while 5-LICAM(S) has greater affinity for bone U(VI), and a 1:1 mixture (total molar ratio = 91) reduced kidney and bone U(VI) to 15 and 58% of control, respectively—more than an equimolar amount of either ligand alone.